Novo Nordisk ends two heart-failure studies early for lack of efficacy
Novo Nordisk said it is ending two heart-failure studies early after concluding it was unlikely ziltivekimab would achieve the expected outcome.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.